BCL2 and chondrosarcoma: Inhibition of Bcl-xl with WEHI-539 led to increased sensitivity to doxorubicin or cisplatin treatment in a subset of chondrosarcoma cell lines, while combination treatment with Bcl-2 inhibitor S55746 and chemotherapy did not result in a difference in sensitivity compared to single treatment (Fig. 2d., supplementary figure 2 and supplementary figure 3).